Facing Up To A Tough Market: Alkermes Execs Hope Vivitrol Alcoholism Med Catches On
This article was originally published in The Pink Sheet Daily
Executive Summary
Unmet need in alcoholism is high, but awareness of drug treatment is low.
You may also be interested in...
Lundbeck/Biotie Aim To Open Up Alcoholism Market By Trying To Reduce, Not Stop, Drinking
H. Lundbeck AS is planning to file for approval in Europe in the second half of 2011 for nalmefene – a drug touted as a novel and potentially revolutionary way of treating alcoholism – but currently is not planning to file in the U.S., presumably due to intellectual property issues.
Lundbeck/Biotie Aim To Open Up Alcoholism Market By Trying To Reduce, Not Stop, Drinking
H. Lundbeck AS is planning to file for approval in Europe in the second half of 2011 for nalmefene – a drug touted as a novel and potentially revolutionary way of treating alcoholism – but currently is not planning to file in the U.S., presumably due to intellectual property issues.
Alkermes Unveils Bydureon Royalties And Its Own Long-acting Form Of Lilly's Zyprexa
Risperdal Consta will be cash cow for years to come, but other drugs in pipeline will fill out revenue stream.